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1. Background 
Since the decade of the 30s the technology starts to improve with an incredible speed. This 
situation has inevitably derivate to the pharmacology or cosmetic field. Nowadays, there are a 
lot of new and better techniques for microencapsulation and, in the future, this will jump to 
the military industry and will derivate to the same situation of nuclear power. After the start of 
this project, there was two PhD students on the UPS working on this field and this help us (all 
the students) to achieve a better knowledge on this field. 
2. Motivation 
The first time Dr. Manel Jose Lis Arias present to me this project, I was surprised. Although the 
microencapsulation start a long time ago, day by day the Scientifics publish new articles and 
the methods and the techniques can change in less than a week. After an initial research, I 
realised this is a new “world” to get explored and I was lucky to get the chance to do it. I hope 
that, with all the work achieved with this project, Dr. Lis and I, we have placed the settlements 
for further investigations on this field and other researchers will be able to benefit of our 
conclusions and experience. 
3. Objective 
The objective of this project is to verify if, using the solvent evaporation technique, the coating 
materials of Polylactic acid, Poly(lactic-co-glycolic acid), Eudragit, Gel-Arab Gum reach the 
same conditions used on the industrial world. Another objective is to get the student the basic 
knowledge of the microencapsulation field. 
4. Gratitude 
First of all I want to give my gratitude to Dr. Manel Lis Arias for all his help during my studies 
on the UPC. Without his help and his in conditional support I could not arrive where I am now. 
Is one of the best professionals I never met and I want to wish him a great life. Besides I want 
to say thanks to all the teacher I met throughout my degree because I could learn all my 
current knowledge.  
On my personal life, I could not arrive here without the support of my family and the 
education they give to me. At least, but not less important, say thanks to my friends for all the 
support since we met. Without them I never have been the human I am now. 
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5. INTRODUTION 
5.1. Microencapsulation 
The definition of microencapsulation is the application of a thin polymer coating to an 
individual molecule or group of molecules (a.k.a. active agent) for protect this from the 
environmental hazards and incress the efectivity during the application of the active molecule 
and to improve the control of the drug release. The capsules obtained have a range of size 
from 5-5000 µm. Microencapsulation is a modified form of film coating, differing only in the 
size of the particles to be coated and the method by which this is produced (Bandi et al. 
2004).Tthis technique is used on the pharmacologic industry, drug industry and chemical 
industry for mention some of the sectors.  
It is necessary to throwback to 1931 to find the first investigation of microencapsulation on 
pharmacology industry, that consisted on preparing gelatine spheres using coacervation 
technique. Since this point the process and the core materials have been improved to reach 
the current situation. to find the first time that a company could successful developed and 
commercialized microcapsules , was on 1951, when The National Cash Register (NCR) create 
carbonless copy paper. Since this point, microencapsulation technology has been constantly 
improve for variety of propose and uses.  
Through history have been use a big range of core materials such as live cells, active enzymes, 
vitamins, fragrances and pharmaceuticals. The most used material as a coat material has been 
the organic polymers (because their characteristics) but their also use fats and waxes. 
The microcapsules offer a great advantage in compeer of the old methods, the main 
advantages are explain below [1]: Patients to consume lower dose for reach the therapeutic 
effect; the risk of side effects decrees; masking of odor or taste for chewable tablets; powders 
and suspensions for children’s medicines; prolong action dosage form; modify the physical 
characters of a material which is required in certain formulations; protect chemicals against 
degradative reactions such as oxidation, dehydration...; controlled and targeted drug delivery;  
diagnostic aids and medicals equipment design, liquids can be handled as solids, safe and 
convenient handling of toxic substances; and separation of incompatible components 
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5.1.1. Morphology and types of microcapsules 
In general, there are two different way to classify the microcapsules: depend their size or 
depend their morphology (the distribution of the core material inside the microcapsule). For 
the first kind of classify them we can find it on the Figure 1: 
 
Figure 1: Terminology of microencapsulation products based on their size [2] 
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If we use their morphology for classify them, there are three groups: if the microcapsules have 
a spherical geometry with a continuous core region surrounded by a continuous shell, the 
group is called mononuclear or continuous core/shell microcapsules; if the microcapsules have 
a irregular geometry and contain a number of particles of core material, the group is called 
multinuclear or polynuclear microcapsules; if the core material is distributed homogeneously 
into the shell material (coating material), the group is called matrix microcapsules. 
Figure 2: Morphology of microcapsules [1]: (A) Mononuclear microcapsule; (B) Multinuclear 
microcapsule; (C) Matrix microcapsule 
 
5.1.2. Techniques for microencapsulation  
Microencapsulation is a multidisciplinary field based on the knowledge and methods of colloid 
chemistry, polymer chemistry, physical chemistry, biochemistry, physics, biotechnology, and 
material sciences [1].  
Microencapsulation techniques are mainly based on the emulsion of the coat material in a 
solution with the coating material and other reagents that improve the efficiency or the 
characteristics of the microcapsules. The way to classify the different types of emulsions is 
based on the composition and morphology of the dispersed and continuous phase. This 
classification can be separate in two groups: if the emulsion is composed by two phases or by 
more than two. 
When the emulsion is composed only by two different phases, thereby it can be a water-in-oil 
emulsion (W/O) where water is the dispersed phase and oil is the continuous phase or oli-in-
water emulsion (O/W) where oil is the dispersed phase and water is the continuous phase. 
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On the other group it appears to have a same situation, on one part if the W/O emulsion is 
dispersed into a water continuous phase it is called an W/O/W emulsion; but, if the O/W 
emulsion is dispersed into an oil continuous phase this is called O/W/O emulsion.  
Another way to classify the microencapsulation process is the technique used for created 
them. There are two big groups depend if the method is chemical or if it is physical. Inside the 
second group it can be split in two other groups, physic-chemical and physic-mechanical (see 
Figure 3). 
Figure 3: Methods of microencapsulation [1] 
As this project is focus on the pharmacological industry, the Figure 4 show the more relevant 
methodologies on this field. 
Figure 4: Microencapsulation methods and their explicabilities [1] 
 
5.2. Antioxidants 
Antioxidants are compound that inhibit oxidation (chemical reaction that can produce free 
radicals). On the plants and animals the antioxidants maintain a complex system to balance the 
oxidative stress; those can be produce internally or give by the dietary. For this reason, in the 
chemical industry they are added to product for prevent oxidation. It is extended use on food, 
cosmetics, pharmacology or in fuel. Moreover, the studies have not been shown any effect of 
them to the health in humans (based on mortality rate or cancer risk). 
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5.2.1. Health effects  
Although certain levels of antioxidant in the diet are required for good health, it is unknown 
which antioxidants are health-promoting in diet. Even though dietary antioxidants have been 
investigated for potential effect on neurodegenerative disease, these studies do not have 
evidence of effects [4].  
5.2.2. Drug candidates 
Common pharmaceuticals with antioxidant properties may interfere with the efficacy of 
certain anticancer medication or radiation [5]. 
5.2.3. Adverse effects 
Relative strong reducing acids can have ant nutrient effects by blinding to dietary minerals in 
the gastrointestinal tract and preventing them from being absorbed [6]. Some of the most 
common antioxidants are showed on the table 1: 
Foods Reducing acid present 
Cocoa bean and chocolate, spinach and turnip Oxalic acid 
Whole grains, maize and legumes Phytic acid 
Tea, beans and cabbage Tannis 
Sweet potato, carrot, pumpkin β-carotene 
Table 1: Most commont antioxidants on food.  
High doses of some antioxidants may have harmful long-term effects. As an example, some 
research show a relation between β-carotene and the in cress of the probability to have lung 
cancer [7]. The subsequent studies confirmed these adverse effects [8]. 
5.2.4. Examples of bioactivity 
Antioxidants can be classified into two broad divisions, if they are soluble in water (hydrophilic) 
or if they are soluble in lipids (lipophilic). In general, water-soluble antioxidants react with 
oxidants in the cell cytosol and the blood plasma, while lipid-soluble antioxidants prtect cell 
membranes from lipid peroxidation [9].These componends may be synthesized in the body or 
obtained from the diet [10]. The relative importance and interaction between these different 
antioxidants is a very complex question, with having synergistic and interdependent effect on 
one another [11] 
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Antioxidant Solubility 
Concentration in human 
serum (μM) 
Concentration in liver 
tissue (μmol/kg) 
Ascorbuc acid 
(vitamin C) 
Water 50–60 260 (human) 
Glutathione Water 4 6,400 (human) 
Lipoic acid Water 0.1–0.7 4–5 (rat) 
Uric acid Water 200–400 1,600 (human) 
Carotenes Lipid β-carotene: 0.5–1 5 (human) 
α-Tocopherol  
(vitamin E) 
Lipid 10–40 50 (human) 
Ubiquinol 
(coenzyme Q) 
Lipid 5 200 (human) 
Table 2: Common antioxidants 
5.2.5. Uses in technology 
5.2.5.1. Food preservatives 
Antioxidants are used as food additives to help guard against food deterioration. Food is 
preserved by keeping in the dark and sealing it in containers or even coating it in wax. 
However, as oxygen is also important for plant respiration, packaging of fresh fruits and 
vegetables contains an 8% oxygen atmosphere.  
5.2.5.2. Industrial uses 
A common use is as stabilizers in fuels and lubricants to prevent oxidation, and in gasoline to 
prevent the polymerization. In 2014, the worldwide market for natural and synthetic 
antioxidants was US$ 2.25 billion with a forecast of growth to US$ 3.25 billion by 2020. 
5.2.6. Β-Carotene 
Is an organic, strongly colored red-orange pigment abundant in plants and fruits of the 
carotenes family. His chemical structure is C40H56 (see Figure 5) and with a molar mass of 
536.888 g/mol. Among the carotenes, is distinguished by having beta-rings at both ends of the 
molecular. In addition is biosynthesized from geranylgeranyl pyrophosphate [12]. β-carotene is 
the most common form of carotene in plants and, in nature, is a precursor to vitamin A via the 
action of beta-carotene 15,15’-monooxygenase [12]. 
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Figure 5: Chemical structure of β-carotene 
 
5.3. Drug delivery 
For several years one of the big goals on the pharmacological industry is to control the drug 
realise of their active components to improve the affectivity of the medicaments. Around the 
decade of 30s, their start to created mathematical models to be able to control this release. 
Over the time have been several scientific whom create different mathematical models for the 
drug realise. Therefore on this project it is necessary to study and explain few of their 
mathematical equations: Higuhi equation [13], N.A. Pappas equations [14] and power law [14]. 
 
5.3.1. Higuhi equation 
 Until 1961 there have been many equations for modelling the drug realises but no one was 
extended used. This year Higughi present his equations and since this point this equation 
became the most famous and often use for describer the release rate of drugs from matrix 
systems. Initially this equation was valid only for planar systems but, over the time, it have 
been modified and extended to consider different geometries and matrix characteristics. The 
basic Higuhi equation is: 
  
 
                                     
(1) 
Where: 
Mt= Comulative absolute amount of drug released at time 
A= Surface area of the controlled release device 
D= Drug diffusivity 
co= Initial drug concentration 
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cs= Solubility of the drug in the polymer 
t= time 
 
This equation can be summarized and expressed as: 
  
    
      
(2) 
Where: 
Minf= Absolute cumulative amount of drug released at infinite time 
K= Constant reflecting the design variables of the system.  
 
However, when Higuhi’s derivation equation is use, there are some situations that should be 
kept in mind [14]: 
Initial drug concentration in the system is higher than the solubility of the drug. This is very 
important because it provide the base for justify the applied the derivation equation (see 
Figure 1). 
The mathematical analysis is based on one-dimensional diffusion. So, edge effects must be 
negligible. 
The suspended drug’s diameter is much smaller that the thickness of the system. 
Swelling or dissolution of the polymer carrier is negligible. 
The diffusivity of the drug is constant. 
Perfect sink conditions are maintained 
 
Figure 6: Pseudo-study state approach [14] 
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5.3.2. Models to describe drug release depend the geometry 
On 1986, Nikolaos A. Peppas create a mathematical model of drug release based on the 
three most common geometries used on drug-delivery systems (thin film, cylindrical 
sample and spherical sample). This mathematical models are based on Fick’s law, whose 
studies are used as base for to almost all the mathematical models since their publishing. 
Release from thin polymer film 
Consider one-dimension thin polymer slab of l thickness, where the system is initially 
maintained at a constant uniform drug concentration (C1) and on the surface are kept on a 
constant drug concentration(C0) became a perfect sink condition. From this situation the 
Fick’s second law, considering a constant drug diffusion coefficient and one-dimensional 
diffusion on x direction, may be written as: 
  
  
  
   
   
 
(4) 
Where 
                            
                                          
 
From this equation, on a trigonometric situation, become on: 
  
    
    
 
         
    
           
  
  
 
   
 
(5) 
A useful interpretation of the equation (4) for short-time behaviour (60% of the release 
drug) can be approximated by [14]: 
  
    
   
  
   
 
   
 
(6) 
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Release from cylinder 
For one-dimensional radial cylinder of radius α, under perfect sink with a constant drug 
diffusion coefficient D, Fick’s second law can be written as [14]: 
  
  
   
   
   
 
 
 
  
  
  
(7) 
Where 
                                  
                                        
 
The solution to Fick’s law under above-specified conditions is: 
  
    
    
 
    
         
   
 
   
 
(8) 
A useful interpretation of the equation (4) for short-time behaviour (10-15% of the release 
drug) can be approximated by: 
  
    
   
  
   
 
   
   
  
   
  
 
 
 
  
   
 
   
   
(9) 
Release for spheres 
For one-dimensional from a sphere of radius α, under perfect sink with a constant drug 
diffusion coefficient D, Fick’s second law can be written as [14]: 
  
  
   
   
   
 
  
 
  
  
  
(10) 
Where 
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The solution to Fick’s law under above-specified conditions is: 
  
    
   
 
  
 
 
  
    
       
  
 
 
   
 
(11) 
A useful interpretation of the equation (4) for short-time behaviour (10-15% of the release 
drug) can be approximated by: 
  
    
   
  
   
 
   
  
  
  
 
(12) 
 
5.3.3. Power law  
It can be extract a semi-empirical equation to describe drug release from polymeric systems 
called power law. This power law depends on Fickian’s diffusion equations; therefore, it can be 
only applied on the 60% of the total release (on some cases only the 10-15%). The general 
equation is [13]: 
  
    
     
(13) 
Where: 
Mt= Absolute cumulative amount of drug released at time 
Minf= Absolute cumulative amount of drug released at infinite time 
K= Constant incorporating structural and geometric characteristics of the device. 
n= Release exponent, indicative of the mechanism of drug release 
 
There are three different situations depending on the n values (this values must be given by an 
experimental test) and the range of values of n is show on the Figure 7.  
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Figure 7: exponent n of the power law and drug release mechanism from polymeric controlled 
delivery systems of different geometry 
Fickian diffusion: The drug realise depend of the time and the geometry and it can be 
controlled. 
Anomalous transport: Indicate the superposition of Fickian diffusion and Zero-order release. 
This situation is only valid for slab geometry. 
Zero-order release: The drug release is independent of time and geometry and it can not be 
controlled. 
5.4. Absorbance 
5.4.1. Basic concepts 
The electromagnetic radiation (known for almost all the population as light) can be described 
as a wave with four properties: wavelength, frequency, velocity and amplitude. However, 
when we speak about absorption, we can not take into account only the previous properties 
and we have to consider the electromagnetic radiation as an energy packages (known as 
photons). In summary, we should consider the electromagnetic radiation as a wave and 
particle  
Wave properties  
For the study of reflexion, refraction and diffraction the electromagnetic radiation can be 
present as a sine wave with magnetically and electrical fields (blue and red respectively and 
the wave direction on black) 
 
Figure 8: Magnetically & electrical fields [1] 
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In our study case, we get into the electrical field. On the figure 2 we can find a 2D 
representation of an electrical field. The x axis show the time of the radiation passing through 
one point.  
Wave characteristics 
The amplitude (A) of the electromagnetically wave is the vector quantity used for measure the 
force of the magnetically or electrical field on his maximum point on the studied wave, 
expressed on cd.  
The period (p) of the radiation is the time passed between successive maximum or minimum 
points (from a wave) through one fixed point, is expressed on seconds (s).  
The frequency (v) is the number of oscillations of the electrically field vector per time unit, 
expressed on s-1, and it is the reverse of the period (1/p). The frequency of any 
electromagnetically wave is determined by the original source and it is constant regardless the 
surface or medium that goes through  
      
(14) 
it shows the relation between the frequency and the velocity (ν) and wavelength (λ). The 
velocity, expressed on cm s-1 or m s-1, unlike the frequency is affected by the source and 
depends on the frequency. The wavelength is the lineal distance between successive 
maximums or minimums of the studied wave. The units used for express the wavelength is 
showed on Table 1 because depend of the spectrum regions. 
Region Unit SI equivalence 
X rays Ångström (Å) 10-10 m 
UV/Vis Nanometers (nm) 10-9 m 
Infrared Micrometers (µm) 10-6 m 
Table 3: Wavelength’s units for some spectrum regions  
Power and intensity of radiation 
The power of radiation (P) is the energy of a beam that reaches one area per unit of time, 
expressed on watts (W), and the intensity of radiation is the power of radiation per solid angel 
unit. Both are proportional to the square of the electrically field amplitude. 
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5.4.2. Radiation absorption 
The absorption process transfer energy to the molecule and decrees the intensity of the 
incident electromagnetically radiation. When this happens the absorption of the radiation 
from the molecules attenuates the beam. This is because each molecular species can absorb 
his own characteristic frequency of electromagnetically radiation. This situation is explained on 
the Beer-Lambert law. 
Absorption process 
The Beer-Lambert law (known as Beer law) show the way that the attenuation grade depends 
on the concentration of the absorbent molecules and the length where the absorption process 
happens. In spectroscopy, the meaning of attenuation is decrees the energy per area of one 
beam of radiation [3]. As we explain before, when the beam of radiation pass through a sample 
(this sample have to be on a liquid medium) this absorb their specific radiation energy causing 
the attenuation of the beam of radiation. This attenuation can increase or decrees because of 
two factors: on a constant medium (related to the longer of the medium) if we have more 
concentration we will have more attenuation; as longer is the medium, the beam of radiation 
find more molecular or atoms on his way and their (the atoms) absorb more radiation.  
 
Figure 9: Attenuation effect [16] 
The figure 2 represents one beam of monochromatic radiation passing through bucket (inside 
with we find our sample) with one specific thickness (l, cm) and one concentration (c, mol/l). 
As we explain before, the attenuation is given by the energy absorption from the sample’s 
atoms. In consequence, the radiant energy decrees while is passing through the bucket from    
to   . The equation 2 show the fraction of radiation that passes through a solution, at a specific 
wavelength, is called transmittance ( ) and it is use to express as a percentage (equation 16) 
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(15) 
   
  
  
     
(16) 
Absorbance 
The absorbance (A) is the common logarithm of the transmittance and it shows the quantity of 
absorb light for the studied analyte. This relation is express on the equation 17 
           
  
 
 
(17) 
Beer law 
According to Beer law, the absorbance is directly proportional to the absorbent’s specie 
concentration ( , g/L) and the thickness of the studied solution ( , cm): 
      
(18) 
Where   is the attenuation coefficient (or extinction coefficient or absorptivity) and their units 
are determinate from the   and . Using our case as an example, the   units are L/(g cm). If we 
relate the concentration in molar units (mol/L), the absorptivity is known as molar attenuation 
coefficient (or molar absorptivity) and the units are L/(mol cm): 
      
(19) 
Application of Beer law 
On the previous section we explain some interference that can affect the lecture of the 
absorbance. Because of this we can not use the equation 6 for know the concentration of our 
sample with only the absorbance. We have to created a calibration curve (or work curve) using 
patron solutions with the same dissolvent and known concentrations. From the calibration 
curve we obtain one linear regression and the following equation 
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(20) 
Where   is the absorbance,   is the anality concentration,   is the ordered in origin of   (only 
when   is zero) and  is the slope. The slope comes from: 
 
Figure 10: Slope 
  
  
  
 
     
     
 
(21) 
Molecular absorption 
There are three kinds of photonic transitions when the molecules are excited by ultraviolet, 
visible or infrared radiation: electronic transition, vibratory transition and rotational transition. 
The two last transition type only happens with polyatomic species because it is necessary a 
central atom that acts like an anchor. 
The electronic transition is caused by the two first radiation type, those exited the molecular 
(or atom) and cause the promotion of one electron from one low energy orbital to one high 
energy orbital. This situation happens when the photon’s energy (  ) is exactly the same 
energy need for this electron to move from one to the other orbital. 
The vibratory transition is the action of the atom’s movements anchored in one central atom. 
The figure 6 shows different types of molecular vibration, on the first row for each vibration 
both atoms get close and away from the central atom (symmetric stretch vibration) or their 
actions are opposite (asymmetric stretch vibration); on the second and third row we fine four 
examples of flexion vibration, the left column represent both atoms acting on the same way 
but the right column their act on the opposite way. 
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The rotational transition is the action of the molecular around his own gravitational centre. As 
an example, we can imagine our molecular like the earth (or any other planet). The earth 
rotates on its own axis and the same happens with our molecular. 
Each transition type has his own energy and the sum of the three give the molecular energy: 
                                     
(22) 
6. Research approach 
6.1. Materials used for manufacturing the microcapsules 
The materials (reagents) used on this project are explained below. 
6.1.1. Biocompatible polymers and active agents 
As it is explained on the objective section, the final use of the microcapsules is to protect the 
human skin. Thereby the coating materials used is biocompatible polymers and they were used 
five: 
Polylactic acid (PLA) (used DCM as a solvent) 
Poly(lactic-co-glycolic acid) (PLGA) (used DCM as a solvent) 
Eudragit (used acetone as a solvent) 
Gel-Arab Gum (used water as a solvent) 
Chitosan (used DCM as a solvent) 
 
The active component used is in all the microencapsulated process is the β-carotene (99% of 
purity) and it was dissolved with 1-propanol because the β-carotene is soluble in water.  
6.1.2. Surfactants and cross-link agent 
There were used many different surfactants on this project. On the first block, it was use 
Paraffin wax, Poly vinyl alcohol (PVA), Styrene maleic anhydride (SMA). For the second block, 
on the first approach it was used the PVA and, on the second approach it was used Tween 20. 
All the surfactants were dissolved using water minus for the paraffine wax because his state is 
liquid. 
The cross-link agent used on the second approach was tannic acid and it was dissolved using 
water.  
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6.1.3. Textile substrates 
The textile substrates used were: Cotton (CO) (Style 400, ISO 105 - F02) and Polyester (PES) 
(Style 777, ISO 105-F04) 
6.2. Experimental methods and techniques  
The methods and techniques used on this project are explained below following the same 
structure according their timing of used. 
6.2.1. Making the microencapsulation 
As it is explained on section 1, there are two blocks of process: one block where it was change 
the coating material; other block were it was studied and improved the system using the same 
coating material. The emulsions used are O/W1/W2 for the approach using different coating 
materials and, on the approach using chitosan as a coating materials, the first emulsion made 
was O/W and the second was O/W1/W2 using conventional solvent evaporation method [2].  
 
Block 1: Different coating material 
On the block 1, there are different reagents used on each approach but the mechanical part 
(during the stirring) is almost the same. The active component (β-carotene) was solved using 
acetone (when the coating material was Gel-Arabic gum or eugardit) or DCM (PLA and PLGA). 
As a coating materials were used 4 different materials: Eugardit (solved with acetone), PLA 
(solved with DCM), PLGA (solved using DCM) and Gel-Arabic gum (solved using distillate 
water). In the case of the surfactant, it was used distillate water in almost every case (less with 
the process of GA).  
The mixture of the core’s solution and the coating’s solution were generated by mechanical 
agitation (Ultra-Turrax T25, Figura 11, Table 4) for several minutes. Besides, with the GA 
process, the mix should be at 50ºC using a thermostated water bath (Frigiterm 6000382, 
Figure 12). The surfactant solutions were mixed by mechanical agitation (Ultra-Turrax T25, 
Figura 11, Table 4) for several minutes. Afterwards, to making the emulsions were mix by 
mechanical agitation (blade starring, Figure 14, Table 6). At last, the mixture was maintained 
under constant agitation until the evaporation of the solvent and the consequent formation of 
microcapsules (around 4h). Furthermore, on the GA process, for heat the reactor it was use a 
thermostated water bath (Frigiterm 6000382, Figure 12).  
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Block 2: Same coating material 
Briefly, on the first approach the active component (β-carotene) and the polymer (chitosan) 
were separately solved using 1-propanol and DCM respectively; the surfactant used is PVA and 
was solved using water. On the other hand, for the second approach the active component 
and the polymer were done with the same method; however, the surfactant used (Tween 20) 
and the cross-link agent (Tannic acid) were separately solved using water as a solvent for both. 
The mixture of the core’s solution and the coating’s solution were generated by mechanical 
agitation (Ultra-Turrax T25, Figura 11, Table 4) for several minutes at 4ºC using a thermostated 
water bath (Frigiterm 6000382, Figure 12). The surfactant solutions and the cross-link agent 
were mixed by mechanical agitation (Magnetic starring, Figure 13, Table 5) for several minutes. 
Afterwards, to making the emulsion O/W or O/W1/W2 were mix by mechanical agitation (blade 
starring, Figure 14, Table 6). At last, the mixture was maintained under constant agitation until 
the evaporation of the solvent and the consequent formation of microcapsules (around 24h). 
 
Figure 11: Ultra-turrax T25 
Manufacturer IKA 
Model T25 
Power 500 W 
Speed range 3500-24000 rpm 
Sample volume 1-2000ml 
Table 4: Specifications of Ultra-turrax T25 
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Figure 12: Frigiterm 6000382 
 
Figure 13: Magentic starring with heating 
Manufacturer J.R. Selecta 
Model 7000343 
Power 630 W 
Speed range 60-1600 rpm 
Sample volume 1-10000ml 
Table 5: Specifications of magnetic starring 
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Figure 14: Blade stirring 
Manufacturer Heidolph 
Model RZA2020 
Power 500 W 
Speed range 500-15000 rpm 
Sample volume 1-2000 ml 
Table 6: Specifications of Heidolph RZA 2020 
6.3. Characterisation of microspheres 
There were done three tests for characterize the microspheres obtained: encapsulations 
efficiency, particle size and drug realise. 
6.3.1. Encapsulation efficiency 
The yield was detected indirectly in the liquid phase by UV/VIS Spectrophotometer (Shimadzu 
UV-2401 PC; Figure 15, Table 7) after centrifugation (Figure 16) for several minutes until the β-
carotene has opted out. The equation use for define the yield is show under these lines: 
      
    
  
     
(23) 
Were: 
C0= Initial concentration of β-carotene. 
C= Concentration of β-carotene after manufacturing the microcapsules. 
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Figure 15: UV/Vis Spectrophotometer 
Manufacturer Shimadzu 
Model 190 to 900 nm 
Power 
Single monochromator with a high-performance blazed holographic grating 
in the aberration corrected Czemy-Tumer mounting 
Speed range 0.1 nm 
Sample 
volume 
50 W halogen lamp (2,000 hours life) and D2 lamp (500 hours life) Personal 
Spectroscopy Software (standard) Spectrum, Quantitative, Time Course 
Table 7: Specifications of UV/Vis Spectrophotometer 
  
Figure 16: Centrifuge 
6.3.2. Particle size 
For discover the average size of the microcapsules first extracted 1 ml from the liquid phase 
and drop few drops to a slide and let it dry on the room. Afterwards, using an optical 
microscope (Figure 18) check the amount of microcapsules and their size.  
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Figure 17: Optical microscope Olympus BX43 
6.3.3. Drug release 
The analyze of the drug on a controlled environmental was used a sample of 0.5 g of tissue, 
previously impregnated with microcapsules solution, inside an Erlenmeyer, at an specific bathe 
ratio with physiologic serum, and this submerged into a bath at a temperature of 37ºC (Figure 
18). The purpose of this is control the hazard effects of the environmental (water or saline 
serum) on the drug release system, simulating the skin’s sweat. 
 
Figure 18: Memmert thermostated water bath 
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7. Experimental part 
7.1. Calibration curve 
Before start with the microencapsulation process, it is necessary to find the way to measure 
the amount of β-carotene microencapsulated (yield) or the results of the drug delivery. For 
that, the calibration curve provides the equation of the relation between the absorbance and 
the concentration (check Application of Beer law). Therefore, is necessary to obtained two 
calibration curve: one for β-carotene without Tween 20 and the other with it (this is because 
the Tween 20 can affect the absorbance of the solution) 
7.1.1. Laboratory process without  
Without Tween 20 
For this part we will made a calibration curve of 20 points with low concentration because 
theoretically it will remain a little amount of β-carotene after the microencapsulation of them. 
The following table show the solutions use for made the calibration curve: 
Concentration (mg/ml) 
0.002 0.004 0.006 0.008 0.01 0.012 0.014 0.016 0.018 
0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.1 
Table 8: Table of concentrations for calibration curve 
When we have the two mother solutions we can start with the preparation of the calibration 
curve’s solutions. On the following table we show the amount of millilitres for each solution on 
a 25 ml volumetric flask:  
Concentration (mg/ml) 0.1 0.09 0.08 0.07 0.06 0.04 0.03 
Volume (ml) 5 4.5 4 3.5 3 2 1.5 
Table 9: Table of millilitres from mother solution 0.5 mg/ml 
Concentration (mg/ml) 0.02 0.018 0.016 0.014 0.012 
Volume (ml) 10 9 8 7 6 
Concentration (mg/ml) 0.01 0.008 0.006 0.004 0.002 
Volume (ml) 5 4 3 2 1 
Table 10: Table of millilitres from mother solution 0.05 mg/ml 
When we have all the solutions ready, using the absorption spectroscopy we read the 
absorbance and we made the calibration curve. 
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With Tween 20 
We want a constant molar ratio between β-carotene and Tween 20, for this reason we made a 
mother solution of β-carotene with Tween 20. As we know for our previous experience, this 
time we only do 10 points for the calibration curve:  
Concentration (mg/ml) 
0.002 0.004 0.006 0.008 0.01 
0.012 0.014 0.016 0.018 0.02 
Table 11: Table of concentrations for calibration curve 
7.1.2. Bloc diagram 
Without Tween 20 
 
Mother solution of 0.5 
mg/ml  with 1-propanol 
for the rank of solution 
from 0.1 to 0.01 
Second solution (from the 
mother solution) of 0.05 
mg/ml with 1-propanol 
for the rank of solution 
from 0.02 to 0.002 
Following the table 2 & 3 
we made all the solutions 
on a volumetric flask of 25 
ml 
Read on the absorption 
spectroscopy the 
absorbance of all the 
solutions  
Obtaine the calibration 
curve and, from those, 
obtaine the Beer law's 
equation 
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It is high recommend getting ready, at less, the half of the solutions before start with the 
absorbance readings and starting the measure from the lowest concentration to the highest 
concentration. 
Figure 19: Different solutions of β-carotene 
 
 
With Tween 20  
 
  
Mother solution of 0.05 
mg/ml  with 1-propanol 
Following the table 3 we 
made all the solutions on 
a volumetric flask of 25 
ml 
Read on the absorption 
spectroscopy the 
absorbance of all the 
solutions  
Obtaine the calibration 
curve and, from those, 
obtaine the Beer law's 
equation 
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7.1.3. Results 
Without Tween 20 
We show the results of the absorbance measure on the following table: 
Concentration 
(mg/ml) 
Molarity  
(mol/l) 
ABS 
481 454 
0.002 3.73E-06 0.163 0.188 
0.004 7.45E-06 0.326 0.375 
0.006 1.12E-05 0.496 0.572 
0.008 1.49E-05 0.654 0.754 
0.01 1.86E-05 0.811 0.934 
0.012 2.24E-05 0.965 1.114 
0.014 2.61E-05 1.053 1.215 
0.016 2.98E-05 1.139 1.314 
0.018 3.35E-05 1.21 1.399 
0.02 3.73E-05 1.748 2.065 
0.03 5.59E-05 1.901 2.275 
0.04 7.45E-05 1.996 2.343 
0.05 9.31E-05 1.497 1.743 
0.06 1.12E-04 1.57 1.827 
0.07 1.30E-04 1.663 1.938 
0.08 1.49E-04 2.344 2.787 
0.09 1.68E-04 1.881 2.202 
0.1 1.86E-04 2.63 3.029 
Table 12: Results of absorbance measurements 
With the results we can obtain the calibration curve and the Beer law’s equation. First we get a 
graphic with all the results for study their behaviour and after we can obtain the equation 
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Figure 20: Calibration curve of both frequencies 
 
As we can see, we find two different behaviours: form the rank 0.002 to 0.012 we see a lineal 
behaviour and from the rank 0.014 to 0.1 we see a non lineal behaviour. The situation of the 
second rank it is because the application of Beer law, the kinetic of the aggregation created 
this distortion on our measurements. Therefore we use the results of the first rank.  
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Figure 21: Calibration curve of 481 nm 
                 
         
(24) 
 
Figure 22: Calibration curve of 454 nm 
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With Tween 20 
We show the results of the absorbance measure on the following table: 
Concentration 
(mg/ml) 
Molarity  
(mol/l) 
ABS 
279 220 
0.002 3.73E-06 0.026 0.078 
0.004 7.45E-06 0.078 0.151 
0.006 1.12E-05 0.152 0.272 
0.008 1.49E-05 0.204 0.316 
0.01 1.86E-05 0.236 0.367 
0.012 2.24E-05 0.247 0.38 
0.014 2.61E-05 0.37 0.569 
0.016 2.98E-05 0.395 0.61 
0.018 3.35E-05 0.313 0.509 
0.02 3.73E-05 0.22 0.48 
Table 13: Results of absorbance measurements 
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Figure 23: Calibration curve of both frequencies 
As we can see, we find two different behaviours: form the rank 0.002 to 0.01 we see a lineal 
behaviour and from the rank 0.012 to 0.02 we see a non lineal behaviour. The situation of the 
second rank it is because the application of Beer law, the kinetic of the aggregation created 
this distortion on our measurements. Therefore we use the results of the first rank.  
 
Figure 24: Calibration curve of 279 nm 
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(25) 
 
Figure 25: Calibration curve of 220 nm 
                
          
(26) 
7.2. Microencapsulation 
The method chosen for to manufacture the microcapsules of betacarothenes with chitosan has 
been Solvent Evaporation. On our first approach it is use only the active agent, the polymeric 
component and a dispersing agent. On the second approach it will be add the surfactant and 
the cross-linking agent on substitution of dispersant. 
7.2.1. Previous calculations 
On this solvent evaporation method it is use the type of emulsion W1/O/W2. On this first 
approach it will be use the following reagents: β-carotene, chitosan (high molar mass) and 
Polyvinyl alcohol (PVA). It will have a constant volume for all the process (until the last step) of 
170 ml (10 ml for β-carotene, 10 ml for chitosan and 150 ml of PVA). For the second approach 
it will have a constant volume of 180 ml (10 ml for β-carotene, 10 ml for chitosan, 150 ml of 
Tween 20 and 10 ml of tannic acid). 
y = 37,15x + 0,0139 
R² = 0,9678 
0 
0,05 
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220 nm 
Lineal (220 nm) 
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First approach using chitosan 
The W1 (active agent) is formed by β-carotene with 1-propanol (as a solvent) because the 
active agent is soluble on water and that fact would difficult the formation of microcapsules. 
As the active agent is the key of the operation, the concentration of it have to be known and 
controlled all the time. On this manufactured process will be 0.1 mg/ml: 
      
         
 
        
       
  
      
  
  
 
(27) 
With the concentration of the mother solution, it can be known the amount of β-carotene for 
made the mother solution on a 100 ml volumetric flask: 
   
  
  
                           
(28) 
The O (polymer) is formed by chitosan with dichloromethane (DCM) (as a solvent) for the same 
reason explained before. It will be use a molar relation of 1:1, then the concentration of this 
polymer on solution should be: 
   
             
  
 
  
      
 
                
                    
 
             
               
 
              
             
 
      
  
      
           
  
 
(29) 
Following the same steps on the previous part, it can be calculate the concentration that a 
mother solution should have: 
      
          
 
        
        
  
        
  
  
 
(30) 
With the concentration of the mother solution, it can be known the amount of chitosan for 
made the mother solution on a 50 ml volumetric flask: 
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(31) 
The W2 (dispersant) is formed by PVA with distillate water (as a solvent). It is use 3.06 g of PVA 
for 150 ml of distillate water. 
Second approach using chitosan 
On this part should be calculate only the amount of product for the Tween 20 and the Tannic 
acid: 
The W2’ (dispersing agent) is formed by Tween 20 with distillate water (as a solvent). It uses a 
rank of concentration of 0.1 – 0.6 g for 400 ml (0.25 mg/ml – 1.5 mg/ml). For this second 
approach, it will be use the high concentration of the rank and add to the emulsion 150 ml, 
then: 
    
  
  
                         
(32) 
For the Tannic acid it was used a concentration of 10% (W/V) on the solution and distillate 
water (as a solvent). For a total volume of 180 ml (10 of them are of Tannic Acid) should make 
a solution of 18 mg per 10 ml. 
   
 
 
 
    
     
     
  
  
    
  
  
                            
7.2.2. Laboratory experiment 
Manufacturing microcapsules using different coating materials (block 1) 
On this part, it was use the laboratory protocols give by O. Perez, one PhD student from the 
university. The explanation below is split depending the coating material used: 
The solution 1 was a mixture of 120 mg of eudragit (coating material) with 6 ml of acetone 
using a beaker of 10 ml and the solution2 was a mixture of 50 mg of β-carotene (active 
component) with 7 ml of acetone using a beaker of 10 ml. Both solutions were stirring using an 
Ultra-Turrax T25 (300 rpm) until the solids were dissolved. Then mix both solutions on a 
beaker of 20 ml, add 10 mg of zinc stearate and stirring throughout 20 minutes (500 rpm). 
While the solution 1 and 2 have been stirring, to make the solution 3 it was use a beaker of 
100 ml mixing 67 ml of paraffin wax and 7.5 ml of hexane. After 20 minutes, pour the emulsion 
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to the solution 3 and stirring with the Ultra-Turrax T25 (15600 rpm) during 10 minutes. 
Afterwards change the starring for a blade stirring (low rate) and left for 4h. 
The solution 1 was a mixture of 250 mg of PLA (coating material) with 10 ml of DCM using a 
beaker of 25 ml and the solution2 was a mixture of 50 mg of β-carotene (active component) 
with 10 ml of DCM using a beaker of 25 ml. Both solutions were stirring using an Ultra-Turrax 
T25 (300 rpm) until the solids were dissolved. Then mix both solutions on a beaker of 50 ml, 
stirring throughout 20 minutes (500 rpm). While the solution 1 and 2 have been stirring, to 
make the solution 3 it was use a beaker of 200 ml mixing 150 ml of water, 250 mg of PVA and 2 
ml of SMA and stirring with a magnetic stirrer (medium rate). After 20 minutes, pour the 
emulsion to the solution 3 and stirring with the Ultra-turrax T25 (15600 rpm) during 10 
minutes. Afterwards change the starring for a blade stirring (low rate) and left for 4h. 
The solution 1 was a mixture of 250 mg of PLGA (coating material) with 10 ml of DCM using a 
beaker of 25 ml and the solution2 was a mixture of 50 mg of β-carotene (active component) 
with 10 ml of DCM using a beaker of 25 ml. Both solutions were stirring using an Ultra-Turrax 
T25 (300 rpm) until the solids were dissolved. Then mix both solutions on a beaker of 50 ml, 
stirring throughout 20 minutes (500 rpm). While the solution 1 and 2 have been stirring, to 
make the solution 3 it was use a beaker of 200 ml mixing 150 ml of water and 2 ml of SMA and 
stirring with a magnetic stirrer (medium rate). After 20 minutes, pour the emulsion to the 
solution 3 and stirring with the Ultra-turrax T25 (15600 rpm) during 10 minutes. Afterwards 
change the starring for a blade stirring (low rate) and left for 4h.  
The solution 1 was a mixture of 4 g of Gel-Arab Gum (coating material) with 50 ml of distillate 
water using a beaker of 100 ml, the solution 2 was a mixture of 10 mg of a solution 1% of β-
carotene with acetone (active component) with 50 ml of distillate water using a beaker of 10 
ml. Both solutions (solution 1 at 50 ºC) were stirring using an Ultra-Turrax T25 (300 rpm) until 
the solids were dissolved. While was the solution 1 and 2 prepare, heat the bath’s reactor at 
50. Then add both solutions to the reactor and, using a blade stirring (600 rpm), mix it and 
keep the pH at 4.26. Thereby use HCl for keep the pH constant. After 90 minutes, decrees the 
bath’s temperature to 8ºC. After 1h adjust the pH, using NaOH, to 9.27. Afterwards add 1g of 
glutaraldehyde and let for 90 minutes the emulsion on a continuous stirring (600 rpm). 
Making the emulsions using chitosan as a coating material (block 2) 
The first step was made the mother solution of W1 and O. For that purpouse, measure the 
amount of reagent need (β-carotene for the first one and chitosan for the second).So, using a 
breaker, made the solution with the reagent and a solvent (1-propanol for the first one and 
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DCM for the second one) stirring it with a magnetically starring (medium velocity) until the 
reagent was dissolved. For to make the solution of dispersing agent the dispersant solution, 
follow the same steps used for the other with the difference on the magnetically stirring step 
(medium rate and 8h waving). 
First approach for made the microencapsulation 
Extract 10 ml of each one and we add to a breaker of 50 ml at least. Mix this solution using an 
Ultra-turrax T25 (9000 rpm) for 15 minutes on a bath at 4ºC. While the solution was stirred, 
made the solution W2. After 15 minutes, pass the emulsion W1/O to a 500 ml beaker, add 150 
ml of W2 there and, using the ultra-turrax T25 (16000 rpm), mix all for 20 minutes. At the end,  
let the solution 24h on a continuous agitation (using a magnetic starring, low velocity) for let 
all the solvent evaporate.  
Second approach for made the microencapsulation 
We extract 10 ml of each one and add to a breaker of 50 ml at least. Mix this solution using an 
ultra-turrax T25 (9000 rpm) for 15 minutes on a bath at 4ºC. In the meantime, made the 
solution W2’ with a beaker of 250 ml and starring the solution with a blade agitator (medium 
velocity). When the emulsion W1/O is ready, pass the solution to the beaker where the 
solution W2’ had been stirred and increases the velocity of the blade agitator. After 15 minutes 
add the Tannic acid, decrease the velocity to “low velocity” and let them 24h for evaporate the 
solvent.  
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7.2.3. Bloc diagram 
Manufacturing microcapsules using eudragit 
 
Manufacturing microcapsules using PLA 
 
Solution 1: 120 mg EU + 
6 ml acetone. Ultra-
turrax T25 (300 rpm) 
until EU dissolve 
Solution 2: 50 mg β-
carotene + 7 ml acetone. 
Ultra-turrax T25 (300 
rpm) until β-carotene  
dissolve 
Mix solution 1 and 2, 
add 10 mg of  zinc 
stearate and stirred 20 
minutes at 500 rpm 
While, solution 3: 67 ml 
of paraffine wax + 7.5 ml 
hexane 
Pour emulsion on 
solution 3, stirring 
withUltra-turrax T25 
(15600 rpm)  for 10 
minutes 
Change to blade stirring 
(low rate) and keep 4h 
for evaporate the 
solvent. 
Solution 1: 250 mg PLA + 
10 ml DCM. Ultra-turrax 
T25 (300 rpm) until PLA 
dissolve 
Solution 2: 50 mg β-
carotene + 10 ml DCM. 
Ultra-turrax T25 (300 
rpm) until β-carotene  
dissolve 
Mix solution 1 and 2 and 
stirred 20 minutes at 
500 rpm 
While, solution 3: 150 ml 
of H2O + 250 mg PVA + 2 
ml SMA. Magentic 
stirring (medium rate). 
Pour emulsion on 
solution 3, stirring 
withUltra-turrax T25 
(15600 rpm)  for 10 
minutes 
Change to blade stirring 
(low rate) and keep 4h 
for evaporate the 
solvent. 
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Manufacturing microcapsules using PLGA 
 
Manufacturing microcapsules using Gel-Arabic gum 
 
 
Solution 1: 250 mg PLGA 
+ 10 ml DCM. Ultra-
turrax T25 (300 rpm) 
until PLGA dissolve 
Solution 2: 50 mg β-
carotene + 10 ml DCM. 
Ultra-turrax T25 (300 
rpm) until β-carotene  
dissolve 
Mix solution 1 and 2 and 
stirred 20 minutes at 
500 rpm 
While, solution 3: 150 ml 
of H2O + 2 ml SMA 
Pour emulsion on 
solution 3, stirring 
withUltra-turrax T25 
(15600 rpm)  for 10 
minutes 
Change to blade stirring 
(low rate) and keep 4h 
for evaporate the 
solvent. 
Solution 1: 4 g GA + 50 
ml H2O. Ultra-turrax 
T25 (300 rpm, 50ºC) 
until GA dissolve 
Solution 2: 10 ml sol. 
1% β-carotene + 50 ml 
H2O. Ultra-turrax T25 
(300 rpm) 
Heat the reactor's bath 
at 50ºC 
Pour solution 1 and 
solution 2 on the 
reactor. Stirring at 600 
rpm  
Adjust pH at 4.26 with 
HCL 
Decress the bath's 
temperature to 8ºC 
after 90 minutes 
Afterwards, adjust pH 
to 9.27 with NaOH 
Add 1g of 
glutaraldehyde 
stirring for 90 minuts at 
600 rpm 
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First approach for made the microencapsulation 
 
10 ml from W1
  
(β-caroten + 1 propanol) 
10 ml from O  
(chitosan + DCM) 
Starring  W1/O with Ultra-
Turrax T25 (9000 rpm) for 
15 minutes. Temperature of 
solution 4ºC 
Add W2 to emulsion W1/O 
and starring with Ultra-
Turrax T25 (16000 rpm) for 
20 minuts. Temperature of 
solutin 4ºC 
Continuous agitation with 
magentical starring (low 
velocity) for 24h 
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Second approach for made the microencapsulation 
 
 
10 ml from W1
  
(β-caroten + 1 propanol) 
10 ml from O  
(chitosan + DCM) 
Starring  W1/O with 
Ultra-Turrax T25 (9000 
rpm) for 15 minutes. 
Temperature of solution 
4ºC 
Pass the emulsion W1/O 
to the emulsion W2'. 
Starring with blade 
agitator (high velocity) 
for 15 minutes 
Add 10 ml of Tannic acid 
with destilatet water to 
the solution W1/O/W2' 
Continuous agitation 
with blade agitator (low 
velocity) for 24h 
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7.2.4. Photos of the process 
 
Figure 26: Ultra-turrax T25 with solution W1/O 
 
 
Figure 27: First approach during the evaporation step 
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Figure 28: Solution of first approach after the process 
7.3. Drug release  
In order to study the mechanisms of drug-delivery from microcapsules, its application into two 
different substrates has been done: cotton (COT) and polyester (PES). The aim of this 
application remains in the fact that microcapsules isolated would tend to aggregate in ionic 
medium. Therefore, results would be not accurate enough to describe, properly the 
phenomenology involved. However, the use of different chemical-based tissues, will allow 
studying the retention potential of the microencapsulated system, and seeing if there’s a 
“reservoir effect”.  
 
7.3.1. Previous calculation  
When do the drug delivery it should have a relation between the weight of the tissue and the 
volume of the solution (1/40). If do not accomplish with this relation the drug delivery results 
will not be a semi-infinite bath, and therefore, diffusion equations will be not applicable. 
Besides, on our test it extracts 10 samples (on a different times) of 1 ml each one. With this 
information, it is possible to calculate the weight of tissue needed: 
 
 52 
 
                                            
(33) 
This is the minimum amount of solution that will be extract during the drug delivery test. With 
that, it is possible to calculate the minimum weight for our tissue sample: 
   
    
 
 
    
   
       
    
         
(34) 
7.3.2. Experimental process 
First of all it is necessary to made two samples, one for each tissue, those weight must be 
higher than 0.25g. When the samples are done, impregnate those samples with microcapsules 
of β-carotene’s solution. Left those samples for 8h until dry and then measure again the 
weight for know the amount of microcapsule there. When the samples are ready, the drug 
delivery test can begin. 
As was explain on the previous section, extract 9 samples for the solutions of the block 1 and 
10 samples from the solution of the block 2. On the following table it is show when we have to 
extract those samples: 
Timing (minute) 
1 3 5 10 15 30 45 60 3600 
Table 13: Timing of sample’s extraction for block 1 
Timing (minute) 
1 3 5 7 10 15 30 45 60 120 
Table 14: Timing of sample’s extraction for block 2 
The drug delivery test has to be at 37 ºC (the average temperature of human skin) for this 
reason it is use a water-bath for reach this temperature on the solution (Figure 29). Before 
start with the test, should be get ready all the test tubes for save the samples from the drug 
delivery’s solution.  
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Figure 29: Erlenmeyer inside Memmert 
Use an Erlenmeyer of 50 ml and add 30 ml of physiological serum with the weave sample. Put 
inside the thermostated water bath (Memmert, Figure 18) and start extraction samples 
following the Table 12 or Table 13. Every time it is extract 1 ml from the drug delivery’s 
solution add 1 ml of physiological serum for not change the total volume of the solution. 
When all the samples are done, those are to get prepare for read the absorbance. Diluted 
them (1:25) with 1-propanol (the same solvent used on the calibration curve) using a 
volumetric flask of 25 ml. 
 
7.3.3. Results 
Manufacturing microcapsules with different coating materials (block 1) 
For release the drug delivery of the microcapsules made with Eudargit, PLA, PLGA and Gel-
Arabic gum it was used as a textile the COT samples. On the following table it show the weight 
of the weave samples before and after the impregnation of microcapsules: 
Coating material used Weight before (mg) Weight after (mg) 
PLA 450 461 
PLGA 418 483 
EU 438 651 
GA 516 522 
Table 15: Weight before and after the impregnation 
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Manufacturing microcapsules with chitosan (block 2) 
The following table show the weight of the weave samples before and after the impregnation 
of microcapsules: 
Wave type Weight before (mg) Weight after (mg) 
COT 473 475 
PES 416 416 
Table 16: Weight before and after the impregnation 
The sample of PES does not change their weight because the chemical characteristics of tissue 
(hydrophobe) cannot absorb a more hydrophilic microcapsules and, therefore, do not let the 
microcapsules adhere. Nevertheless, may be microcapsules only on the COT sample. Spite of 
that, the drug delivery test should be done for the PES samples in case it have a low 
concentration of microcapsules (our weight balance can not read under the milligrams). 
Start with the absorbance test and obtained lectures on the frequency 481 nm and 479 nm 
(see Figures 30 and 31) on the COT test but did not obtain any lecture on the PET test (this 
confirm our hypothesis). The results obtained on the COT test are showed on the following 
table: 
Time (minute) 481 nm 479 nm 
1 0.01 0.012 
3 0.035 0.041 
5 0.0078 0.009 
7 0.002 0.002 
10 0.002 0.002 
15 0 0 
30 0 0 
45 0 0 
60 0 0 
120 0 0 
Table 17: ABS results of COT test 
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Figure 30: All absorbance results from COT test 
The results from drug delivery test show that, after 15 minutes, there are no more 
microcapsules of β-carotene. This is due to the effect of the temperature to the β-carotene. As 
a consequence of the degradation temperature of the β-carotene, after a few minutes the β-
carotene was demoting. 
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The result from the drug delivery test on PES is show on the following table: 
Time (minute) 481 nm 479 nm 
1 0 0 
3 0 0 
5 0 0 
7 0 0 
10 0 0 
15 0 0 
30 0 0 
45 0 0 
60 0 0 
120 0 0 
Table 18: ABS results of PES test 
 
Figure 31: All absorbance results from COT test 
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7.4. Yield 
7.4.1. Preparation of the samples  
It is extracted several samples from the microcapsule’s solution and, using a centrifuge, we 
decant the microcapsules from the supernatant solution. This is done for leave only the excess 
of β-carotene on the solution. After a while it is possible to see (on the bottom) the 
microcapsules, if not keep with the centrifugation until this situation success. 
Now, extract 2.5 ml (it is use a dilutee’s relation of 1:10 form the original sample) of the 
sample and it is pass to a volumetric flask of 25 ml. We full fill it with 1-propanol. Before start 
with the absorbance readings it should been ready four different samples for each approach. 
7.4.2. Bloc diagram 
 
  
Extract samples from 
microcapsule's 
solution 
Centrifuge the 
samples for decant 
the microcapsules  
Extract 2.5 ml from 
the sample and 
diluate with 1-
propanol 
Read the absorbance 
and  record the ABS 
at 481, 454, 279 and 
220 nm 
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7.4.3. Results 
First approach 
On the first approach, the absorbance at 279 nm and 220 nm it does not necessary to be read. 
This is because, on the microcapsule’s solution, it does not have Tween 20. The measurement 
of the absorbance is showed on the next table: 
Sample 481 nm 454 nm 
1 0.53 0.61 
2 0.48 0.579 
3 0.506 0.541 
4 0.445 0.513 
Table 20: Absorbance form the first approach  
Using the equations obtained with the calibration curve, it can be obtained the yield of the first 
approach: 
Sample 
Concentration (mg/ml) diluted Concentration (mg/ml) Yield (%) 
481 nm 454 nm 481 nm 454 nm 481 nm 454 nm 
1 0.00651 0.00649 0.06512 0.06485 34.88 35.15 
2 0.00589 0.00615 0.05890 0.06154 41.10 38.46 
3 0.00621 0.00575 0.06213 0.05748 37.87 42.52 
4 0.00545 0.00545 0.05454 0.05448 45.46 45.52 
Table 21: Yield on the first approach 
With the first approach, it is obtained a yield of 40.12%. This result is good and promising 
because it was not used the surfactant and cross-linking agent (two components that help with 
the creation of microcapsules).  
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Second approach 
Maybe the Tween 20 did not react completely and it can remain some of them on the 
microcapsule’s solution. Therefore it should be read the absorbance at all the frequencies. The 
measurement of the absorbance is showed on the next table: 
Sample 481 nm 454 nm 279 nm 220 nm 
1 0.202 0.236 0.538 1.071 
2 0.199 0.230 0.523 1.045 
3 0.2 0.233 0.532 1.062 
4 0.194 0.228 0.520 1.031 
Table 22: Absorbance form the second approach 
If it is done a quick read of these lectures, the results from 279 nm and 220 nm are out or 
range and the results are not good. Spite of that, it must be calculate them and the results are: 
Sample 
Concentration (mg/ml) diluted Concentration (mg/ml) Yield (%) 
279 nm 220 nm 279 nm 220 nm 279 nm 220 nm 
1 0,02061 0,02738 0,20608 0,27378 -106.81 -173.72 
2 0,02006 0,02775 0,20059 0,27755 -100.59 -177.55 
3 0,02039 0,02821 0,20388 0,28213 -103.88 -182.13 
4 0,01995 0.02845 0,19948 0,28454 -99.49 -184.55 
Table 23: Yield on the first approach for 279 nm and 220 nm 
The hypothesis done on before the yield calculation is right therefore we only use the 
absorbances lectures form 481 nm and 454 nm: 
Sample 
Concentration (mg/ml) diluted Concentration (mg/ml) Yield (%) 
481 nm 454 nm 481 nm 454 nm 481 nm 454 nm 
1 0.00243 0.00249 0.02429 0.02487 75.71 75.13 
2 0.00239 0.00242 0.02391 0.02423 76.09 75.77 
3 0.00240 0.00246 0.02404 0.02455 75.96 75.45 
4 0.00233 0.00240 0.02329 0.02402 76.71 75.98 
Table 24: Yield on the second approach 
On the second approach, the average yield obtained is 75.84%. This result is very good 
because almost all the β-carotene was microencapsulate and this result is near the yield it can 
be find on the industrial word (around 85%). 
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7.5. Characterization 
7.5.1. Physical characteristic 
Physical characteristics of block 1 
Due a problem on the equipments, it was no possible to run the test for the samples of PLGA 
and Gel-Arabic Gum. However, it was possible to run the test for the samples of Eudargit and 
PLA.  
 
 
Figure 32: Microspheres of EU 
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Size Agglomeration  Olfactory intensity Color 
20-35µm No ------ White 
Table 25: Characteristics of microcapsules of EU 
 
 
Figure 33: Microspheres of PLA 
Size Agglomeration  Olfactory intensity Color 
1 µm No ------ Orange 
Table 26: Characteristics of microcapsules of PLA 
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Physical characteristics of block 2 
Using an optical microscope, it can be known the size of the microcapsules manufactured and 
the amount of them (always on the samples studied).  
 
Figure 34: Image capture from the optical microscope, 5 x 0.1 
 
Figure 35: Image capture from the optical microscope, 50 x 0.75 
Size Agglomeration  Olfactory intensity Color 
6-16µm No ------ White 
Table 27: Characteristics of microcapsules of chitosan 
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7.5.2. Theoretical mechanism of drug realise 
Drug realise of block 1 
The results obtained on the drug delivery test were good enough as not to have to apply any 
correction factor. Below there is a table and a graphic with the results corresponding to the 
absorbance of 481 nm (this is due the results on this spectrum were much better than the 
results on 454 nm): 
Time (min) ABS Concentration (mg/ml) M (mol/l) Mt/Minf    
0 0 0 0 0 0 
1 0.121 0.516 9.609E-04 1.01592 1 
3 0.125 0.548 1.021E-03 1.07942 1.73205081 
5 0.1173 0.486 9.051E-04 0.95696 2.23606798 
10 0.1177 0.489 9.113E-04 0.96348 2.64575131 
15 0.1179 0.491 9.141E-04 0.96649 3.16227766 
30 0.1179 0.491 9.141E-04 0.96649 3.87298335 
45 0.121 0.516 9.609E-04 1.01592 5.47722558 
60 0.116 0.476 8.858E-04 0.93655 6.70820393 
3600 0.12 0.508 9.458E-04 1.00005 7.74596669 
Table 28: Results of PLA 
Time (min) ABS Concentration (mg/ml) M (mol/l) Mt/Minf    
0 0 0 0 0 0 
1 0.0635 0.0524 9.759E-05 0.11217 1 
3 0.1133 0.4541 8.458E-04 0.97224 1.73205081 
5 0.114 0.4594 8.558E-04 0.98364 2.23606798 
10 0.114 0.4594 8.558E-04 0.98364 2.64575131 
15 0.114 0.4594 8.558E-04 0.98364 3.16227766 
30 0.115 0.4675 8.708E-04 1.00090 3.87298335 
45 0.114 0.4594 8.558E-04 0.98364 5.47722558 
60 0.115 0.4675 8.708E-04 1.00090 6.70820393 
3600 0.115 0.4675 8.708E-04 1.00090 7.74596669 
Table 29: Results of PLGA 
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Time (min) ABS Concentration (mg/ml) M (mol/l) Mt/Minf    
0 0 0 0 0 0 
1 0.123 0.5319 9.909E-04 1.04856 1 
3 0.125 0.5481 1.021E-03 1.08033 1.73205081 
5 0.122 0.5239 9.759E-04 1.03267 2.23606798 
10 0.1165 0.4795 8.932E-04 0.94520 2.64575131 
15 0.114 0.4594 8.558E-04 0.90557 3.16227766 
30 0.114 0.4594 8.558E-04 0.90557 3.87298335 
45 0.114 0.4594 8.558E-04 0.90557 5.47722558 
60 0.122 0.5239 9.759E-04 1.03267 6.70820393 
3600 0.12 0.5078 9.458E-04 1.00090 7.74596669 
Table 30: Results of EU 
Time (min) ABS Concentration (mg/ml) M (mol/l) Mt/Minf    
0 0 0 0 0 0 
1 0.115 0.4675 8.708E-04 0.79162 1 
3 0.122 0.5239 9.759E-04 0.88716 1.73205081 
5 0.117 0.4836 9.008E-04 0.81891 2.23606798 
10 0.114 0.4594 8.558E-04 0.77797 2.64575131 
15 0.129 0.5803 1.081E-03 0.98270 3.16227766 
30 0.1287 0.5777 1.076E-03 0.97831 3.87298335 
45 0.114 0.4594 8.558E-04 0.77797 5.47722558 
60 0.124 0.54 1.006E-03 0.91445 6.70820393 
3600 0.132 0.6045 1.126E-03 1.02364 7.74596669 
Table 31: Results of GA 
From this point, and in order to obtain the mathematic model of the drug realise, we must 
graphic all the results on two different graphics:  
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Figure 36 
 
Just in order to see the accumulation of points in the first times of the delivery. is usual 
recommended to avoid the equilibrium point. 
 
Figure 37 
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Figure 38 
 
 
Figure 39 
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Figure 40 
 
 
Figure 41 
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Figure 42 
 
 
Figure 43 
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At this point it is necessary to use the equation of Krosenmeyer-Peppas (also knon as Power 
law) for calculate the valour of n and the k (equation 4.3). If the result of n is inside the Fick’s 
parameters (see Figure 7). This let as continuous with the Higuchi’s study. 
With all the information extracted from the graphics, it can be calculated the valour of n and K 
on any point. The table 3 summarize this valour: 
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(36) 
Coating material n K (mol/l*minute) 
PLA 0.055 0.574 
PLGA 1.96 0.538 
EU 0.027 0.575 
GA 0.103 0.507 
Table 32: Results of Krossenmeyer-Peppas equation for block 1 
Almost all the valour of n are under 0.5, thereby they have Fickian diffusion and let us to apply 
the higuhi equations. However, the n result of PLGA means that the drug realize is 
independent of time, regardless the geometry. Regardless this situation, this valour will not be 
considerate and beyond this point it is used the valour n=0.5 on the Higughi’s equation. 
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Figure 44: Higuhi comparation for block 1 
 
Figure 45: Higuhi comparation (avowing equilibrium point) for block 1 
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For the Higughi model it is necessary to use his equation for spear explained on the section 
4.3: 
  
    
     
 
   
(37) 
  
    
 
  
 
 
 
  
 
 
  
  
 
   
(38) 
Coating material D (mol/cm2) KH (mol/l*minute) 
PLA 0.0499 1.01542 
PLGA - 0.11217 
EU 38.92 1.04856 
GA - 0.79162 
Table 33: Valour of D and KH on the block 1 
Drug realise of block 2 
As it is show on the section drug delivery. those are few samples without β-carotene. Thereby 
we “apply” a factor of 0.0069 for 481 nm and 0.0033 for 454 nm (there are the b on each 
calibration curve’s equation) for not have a negative results while those equations are apply. 
All the calculations are done only for the cotton data. The following table show those results: 
Time (min) ABS Concentration (mg/ml) M (mol/l) Mt/Minf    
0 0 0 0 0 0 
1 0.882 3.112E-03 5.797E-06 0.28571 1 
3 0.157 1.089E-02 2.029E-05 1.00000 1.73205081 
5 0.057 1.867E-03 3.478E-06 0.17143 2.23606798 
7 0.057 6.224E-04 1.159E-06 0.05714 2.64575131 
10 0.007 6.224E-04 1.159E-06 0.05714 3.16227766 
15 0.007 0.000E+00 0.000E+00 0.00000 3.87298335 
30 0.007 0.000E+00 0.000E+00 0.00000 5.47722558 
45 0.007 0.000E+00 0.000E+00 0.00000 6.70820393 
60 0.007 0.000E+00 0.000E+00 0.00000 7.74596669 
120 0.257 0.000E+00 0.000E+00 0.00000 10.9544512 
Table 34: Results for 481 nm 
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Time (min) ABS Concentration (mg/ml) M (mol/l) Mt/Minf    
0 0 0 0 0.00000 0 
1 0.307 3.245E-03 6.045E-06 0.29516 1 
3 1.032 1.100E-02 2.048E-05 1.00000 1.73205081 
5 0.182 1.909E-03 3.556E-06 0.17363 2.23606798 
7 0.057 5.730E-04 1.067E-06 0.05211 2.64575131 
10 0.057 5.730E-04 1.067E-06 0.05211 3.16227766 
15 0.003 0.000E+00 0.000E+00 0.00000 3.87298335 
30 0.003 0.000E+00 0.000E+00 0.00000 5.47722558 
45 0.003 0.000E+00 0.000E+00 0.00000 6.70820393 
60 0.003 0.000E+00 0.000E+00 0.00000 7.74596669 
120 0.003 0.000E+00 0.000E+00 0.00000 10.9544512 
Table 35: Results for 454 nm 
 
The results from the data of 481 nm and 454 nm are almost equals. for this reason all the 
graphics since this point are quite similar. Therefore there will be one graphic for each 
frequency: 
Figure 46 
Just in order to see the accumulation of points in the first times of the delivery. is usual 
recommended to avoid the equilibrium point. 
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Figure 47 
 
Figure 48 
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Figure 49 
 
With all the information extracted from the graphics, it can be calculated the valour of n  and K 
on any point. The table 3 summarize this valour: 
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(41) 
Frequencies n K (mg/ml*minute) 
481 2.45 0.0194 
454 2.39 0.2137 
Table 35: Results of Krossenmeyer-Peppas equation of block 2 
 
The valour of n means that the drug realize is independent of time. regardless the geometry. 
However, we spouse that this valour is n=0.5 ( limit superior Fickian diffusion) and this let us 
apply Higughi and know the drug diffusion coefficient. D (equation 43).  
0,00000 
0,20000 
0,40000 
0,60000 
0,80000 
1,00000 
1,20000 
0 2 4 6 8 10 12 
M
t/
M
in
f 
τ (min) 
Beta carotene delivery in Chitosan (0-10 min) 
(454 nm) 
 75 
 
Figure 50 
Figure 51 
For the Higughi model it is necessary to use his equation for spear explained on the section 
4.3: 
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7.5.3. Conclusions 
As can be seen from the graphic (Fig.  ) of the block 1, except the case of PLGA, every 
microencapsulated system, shows , from the first moment, a “burst” effect. Basically, all the 
concentration is capable to deliver to the system (equilibrium) has moved out from the 
microcapsule.   
That fact can be attributed to the lack of stability of the microcapsules formed. Although they 
seem really stable, the swelling effect of water molecules is capable to affect the whole 
structure. Therefore, this protocols, should be avoided because they cannot give to the 
system, a regular a sustained dose.   
By the contrary, the polarity of the OH groups in the PLGA copolymer, create more intense 
interactions between the polymeric chains that constitute the shell part of the microcapsule. 
Therefore, until the PLGA molecular chains are not hydrolyzed by water, they are not able to 
deliver the beta-carotene retained inside. Nevertheless, all these first approaches seem to be 
not good for the purpose planned at the beginning of the work.   
It should be necessary to develop different protocols using (as seen from the results) more 
polar polymer structures (more soluble, more similar to the beta-carotene chemical 
composition) , that have the possibility to make an stable mixture with other polar chains to 
“catch” chemically, the beta-carotene molecules, as for example, Chitosan.  
As a result of the drug release of the block 1, it was changed the coating material to Chitosan. 
The results of the drug release were promising despite the degradation of the β-carotene. This 
could be done because of the molecular interaction, besides one of the most common use of 
β-carotene is on human skin.  
8. Conclusions 
After running all the test the conclusion is that the coating material used on the block 1 is 
better for contain the β-carotene and protect them from the environmental hazards. 
Nevertheless using the chitosan as a coating material the yield was improve to an industrial 
valour, proving the viability of this technique into the cosmetic or pharmacologic industry. 
If we want to improve the technique, it highly recommends changing the surfactant for change 
the conditions and do not lose the β-carotene after 10-15 minutes. On the other hand, it is 
possible to change the Chitosan to a low or high molecular weight and check their behaviour 
on the drug realise and microencapsulation process.  
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9. Annex 
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9.2. Security data sheet Chitosan 
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9.3. Security data sheet Acetone 
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9.4. Security sheet Gum Arabic 
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9.5. Security data sheet β-carotene 
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9.6. Security data sheet Dichloromethane 
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9.7. Security data sheet Paraffin wax 
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9.8. Poly(lactic-co-glycolic acid) 
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9.9. Polylactide 
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9.10. Security data sheet Poly(vinyl alcohol) 
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9.11. Security data sheet  
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9.12. Security data sheet Tween 20 
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9.13. Security data sheet Zinc Stearete  
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